SCHEMBL15036339

SCHEMBL15036339

CC(C)C#Cc1cc2cnc(Nc3ccc(OC4CCNC4)cc3)nc2n(Cc2ccccc2CC(F)(F)F)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.36
RCOR1 Q9UKL0 2/20 0.36
CDK4 P11802 5/20 0.35
CCND1 P24385 5/20 0.35
CCNA2 P20248 4/20 0.35
CDK2 P24941 4/20 0.35
RIPK2 O43353 4/20 0.35
ACVR1 Q04771 4/20 0.35
NOD2 Q9HC29 4/20 0.35
TBK1 Q9UHD2 1/20 0.35
FGFR1 P11362 3/20 0.34
FGFR2 P21802 3/20 0.34
FGFR4 P22455 3/20 0.34
FGFR3 P22607 3/20 0.34
CHEK1 O14757 2/20 0.34
CACNA2D1 P54289 1/20 0.34
CAMK2D Q13557 1/20 0.34
PTK2 Q05397 2/20 0.34
CCNB2 O95067 1/20 0.33
CCNE2 O96020 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15617465 0.93 CDK4 (0.39) KDM1ARCOR1CDK4CCND1CCNA2
SCHEMBL15036456 0.77 PTK2 (0.43) CDK4CCND1PTK2CCND2CCND3
SCHEMBL15036309 0.77 CAMK2D (0.36) CDK4CCND1CCNA2CDK2RIPK2
SCHEMBL15036219 0.76 TNK2 (0.40) CDK4CCND1CCNA2CDK2TBK1
SCHEMBL15036172 0.76 CDK4 (0.37) CDK4CCND1CCNA2CDK2TBK1
SCHEMBL15036287 0.76 MAP4K1 (0.40) RIPK2ACVR1NOD2CHEK1CACNA2D1
SCHEMBL15041728 0.76 RIPK2 (0.36) KDM1ARCOR1CDK4CCND1CCNA2
SCHEMBL15258240 0.76 CDK4 (0.39) CDK4CCND1CCNA2CDK2TBK1
SCHEMBL15036406 0.76 CHEK1 (0.35) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15036273 0.75 CDK4 (0.35) KDM1ARCOR1CDK4CCND1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680099-B2 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-03-25 US disclosed
US-20130245012-A1 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-19 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245012-A1 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK3 KDM1A 2795/4885RCOR1 3896/4885CDK4 397/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 KDM1A 1838/4885RCOR1 2728/4885CDK4 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.